Ann Pharmacol Pharm | Volume 5, Issue 5 | Short Communication | Open Access

Ciprofloxacin in Neonatology

Lagrine M^1,2, Bennaoui F^1,2*, Idrissi Slitine N^1,2 and Maoulainine FM^1,2

¹Department of Neonatal Intensive Care, Mohammed VI University Hospital and Research, Morocco
²Child Health and Development Research Laboratory, Cadi Ayyad University, Morocco

^*Correspondance to: Bennaoui F 

Fulltext PDF

Abstract

Introduction: Ciprofloxacin has often been used in off-label pediatrics. In neonatology, its use, although rare, is authorized in the event of a life-threatening infection. Material and methods: We conducted a retrospective study over a period from January 2017 to September 2019. Ciprofloxacin was prescribed in 13 newborns. The interest of our study is to report the experience of the neonatal intensive care unit at the Mohammed VI hospital center in Marrakech with regard to the use of quinolones and to compare these benefits/risks. Results: The most common reason for admission was neonatal seizures in 30.8%, followed by neonatal respiratory distress in 23.1%. Among the indications: Nosocomial infection in 53.8% with the isolation of 3 cases of Klebsiella pneumonia, 2 cases of Enterobacter cloacae, one case of Klebsiella pneumonia associated with Enterobacter cloacae and one case of Acinetobacter baumani; followed by ventriculitis in 23.1%. No immediate side effects have been identified. At the end of the treatment, 9 newborns were cured against 4 deceased cases. Conclusion: Ciprofloxacin can be a good therapeutic choice in case of lethal infection. Their side effects are rare.

Keywords:

Newborn; Ciprofloxacin; Multidrug-resistance seeds

Citation:

Lagrine M, Bennaoui F, Idrissi Slitine N, Maoulainine FM. Ciprofloxacin in Neonatology. Ann Pharmacol Pharm. 2020;5(5):1193.